Browse the corpus

Serum prostate-specific antigen testing is the primary method for screening and early detection of prostate cancer. This testing is known for its sensitivity but is limited by low specificity. Elevated levels of prostate-specific antigen can result from benign conditions, leading to potential overdiagnosis and unnecessary biopsies, which strain healthcare resources. Ideal biomarkers are highly sensitive and specific, easy to use, cost-effective, and approved by relevant health authorities, enhancing their use in clinical practice. This activity discusses risk-stratification biomarkers designed for lower-risk and borderline patients, typically with prostate-specific antigen levels between 4 and 10 ng/mL, and the interpretation of test results, including avoiding further invasive diagnostics for negative results, thereby reducing unnecessary procedures or diagnostic biopsies for high-risk patients. This course reviews current and investigational biomarkers, including blood- and urine-based assays, and their integration into clinical practice to improve diagnostic accuracy by supplementing prostate-specific antigen testing. Participants will also gain an understanding of each biomarker's unique advantages for detecting, diagnosing, and monitoring prostate cancer, as well as risk assessment tools to support better clinical decision-making. This activity for healthcare professionals is designed to enhance the learner's competence in applying risk-stratification biomarkers, identifying high-risk patients, interpreting test results across patient populations, and implementing an appropriate interprofessional approach when integrating this tool into clinical practice to ensure early and accurate detection of prostate cancer and improve patient outcomes. Objectives: Identify the challenges of adopting serum prostate-specific antigen as the only biomarker for diagnosing prostate cancer in various patient populations. Interpret various biomarker assays for elevated prostate-specific antigen risk analysis. Compare the available biomarker assays for elevated prostate-specific antigen risk analysis. Implement interprofessional team strategies to improve care coordination and patient outcomes using biomarker assays for elevated prostate-specific antigen risk analysis. Access free multiple choice questions on this topic.

Prostate cancer ranks among the most frequently detected malignancies in males, accounting for approximately 1.4 million new cases worldwide each year.[1] This disease represents the most commonly diagnosed cancer and the second leading cause of cancer-related mortality in men, with an estimated 2.4 million cases projected for 2040, according to the National Cancer Institute (NCI). Approximately 1 in 8 men develops prostate cancer over a lifetime. Despite this high incidence, the typically indolent disease course contributes to a mortality rate of only 1 in 41 diagnosed men. One of the most effective approaches for screening, diagnosis, staging, assessment of therapeutic response, and prognostication in prostate cancer involves the use of serum or urine biomarkers for risk assessment. The NCI defines a biomarker as a biological molecule identified in blood, urine, other body fluids, or tissues that signals an abnormal process, condition, or disease. Appropriate application of biomarkers allows healthcare professionals to individualize diagnostic strategies while minimizing unnecessary diagnostic interventions and reducing the risk of overtreatment. The Early Detection Research Network represents an NCI-led initiative focused on identifying, developing, and validating novel biomarkers and emerging technologies to improve the accuracy and timeliness of cancer diagnosis. These biomarkers may include proteins, DNA, messenger RNA (mRNA), metabolites, prostate cancer cells or their derivatives, exosomes, or measurements of cellular processes, eg, proliferation or apoptosis. Several commercial risk-stratification biomarkers now support clinical evaluation of patients with persistently elevated prostate-specific antigen (PSA) levels and suspected prostate cancer. Beyond guiding clinical decision-making in low- or intermediate-risk patients with equivocal PSA values, surrogate biomarkers may be useful for assessing an individual patient’s response to a specific drug, procedure, or therapeutic intervention. Through this role, a biomarker can monitor treatment effectiveness for a defined disease or condition. Validated surrogate risk-stratification biomarkers frequently spare patients from prolonged clinical trials, unnecessary biopsies, costly imaging studies, or other invasive tissue-based diagnostic procedures.[2]

Beyond guiding clinical decision-making in low- or intermediate-risk patients with equivocal PSA values, surrogate biomarkers may be useful for assessing an individual patient’s response to a specific drug, procedure, or therapeutic intervention. Through this role, a biomarker can monitor treatment effectiveness for a defined disease or condition. Validated surrogate risk-stratification biomarkers frequently spare patients from prolonged clinical trials, unnecessary biopsies, costly imaging studies, or other invasive tissue-based diagnostic procedures.[2] An ideal biomarker demonstrates high sensitivity and specificity, straightforward use and interpretation, cost-effectiveness, broad availability, reproducibility, and reliable quantification from an easily obtainable specimen. Additional essential characteristics include a negative predictive value of at least 90%, approval by the Food and Drug Administration (FDA), compliance with Clinical Laboratory Improvement Amendments (CLIA) standards, and endorsement by the National Comprehensive Cancer Network (NCCN). Prostatic risk-stratification biomarkers serve primarily lower-risk and carefully selected borderline patients with mildly elevated PSA concentrations, generally ranging from 4 to 10 ng/mL, in whom unfavorable results often lead to avoidance of immediate additional testing, prostate imaging, biopsies, or other diagnostic procedures.[1][2] This activity examines the current landscape of available risk-stratification biomarkers as well as those under active investigation.

Inflammation of the prostate gland, often caused by various genetic mutations, is the earliest sign of prostate cancer. This inflammation leads to oxidative damage, which causes telomeres at the ends of chromosomes to shorten, eventually initiating the development of prostate cancer. Several genes, including MYC, PTEN, NKX3.1, and the TMPRSS2-ERG gene fusion, have been identified in the initiation and development of prostate cancer, even though no single tumor suppressor gene is primarily responsible. The TMPRSS2-ERG gene fusion activates the ERG oncogenic pathway, which is linked to disease emergence. The reactivation of cell cycle pathways leads to unchecked cell proliferation, promoting tumor metastasis. Gene expression profiling of metastatic disease identifies overexpression of EZH2 mRNA and proteins. Due to its role in apoptosis and proliferation, EZH2 is currently under research as a new prostate cancer target.

Optimal use of risk-stratification biomarker assays for prostate cancer can significantly reduce unnecessary diagnostic procedures and treatments. The healthcare team should be familiar with implementing these assays when appropriate and help educate the patient and family when necessary or requested. The screening, diagnosis, and treatment must be individualized based on age, high-risk characteristics, comorbid conditions, life expectancy, and personal preferences. The patient must be empowered to make appropriate decisions through interdisciplinary team consultations and effective communication between the patient and clinicians. Overtreatment, due to adverse effects, can cause harm to the patient, adversely affecting his quality of life and placing the patient under undue psychological distress. Eligible patients may be spared from such adversities by utilizing active surveillance protocols. The past decade saw a paradigm shift in the management of prostate malignancy. With advances in diagnostics, imaging, genetics, and metabolomics, the evaluation and management of prostate malignancy have become even more complex. However, there needs to be more consensus on various diagnostic and treatment protocols, and different expert guidelines fall short of offering concrete recommendations. Interprofessional agreement and coordination are crucial for improving prostate cancer outcomes. To provide the patient with the best care possible, a team of specially qualified nurses, technicians, general practitioners, advanced practitioners, pharmacists, genetic counselors, psychotherapists, oncologists, radiologists, urologists, and allied healthcare workers must collaborate. Physicians and general practitioners evaluate risk, interpret biomarker results, and integrate findings into shared decision-making. Advanced practitioners support longitudinal monitoring and patient counseling. Nurses reinforce education, ensure adherence to testing and follow-up, and monitor adverse outcomes. Pharmacists contribute by assessing therapeutic response and medication safety, while other health professionals facilitate diagnostic coordination and patient navigation. Effective communication and collaboration across disciplines enhance patient-centered care, improve outcomes, strengthen safety, and optimize team performance.